CHICAGO--(BUSINESS WIRE)--Massive Bio, a global company specializing in AI-powered clinical trial matching and oncology data solutions, is participating in the 2025 American Society of Clinical ...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials ...

BALTIMORE--(BUSINESS WIRE)--Infinity Bio is pleased to announce the release of their MuSIGHT™ mouse autoantibody reactome service offering. Defining an animal’s autoantibody reactome – the set of all ...

New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User ...

Bio-Med Devices Inc. has been shaping the future of respiratory care for over 50 years, but its story is more than a timeline – it’s a legacy built on family, risk and deep-rooted purpose. The company ...